CN105749277A - Yolk bioprotein foam filler and preparation method thereof - Google Patents
Yolk bioprotein foam filler and preparation method thereof Download PDFInfo
- Publication number
- CN105749277A CN105749277A CN201610135567.9A CN201610135567A CN105749277A CN 105749277 A CN105749277 A CN 105749277A CN 201610135567 A CN201610135567 A CN 201610135567A CN 105749277 A CN105749277 A CN 105749277A
- Authority
- CN
- China
- Prior art keywords
- yolk
- bioprotein
- foam
- tamping
- livetin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002969 egg yolk Anatomy 0.000 title claims abstract description 43
- 239000006260 foam Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 22
- 239000000945 filler Substances 0.000 title abstract description 4
- 244000052769 pathogen Species 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 239000011159 matrix material Substances 0.000 claims abstract description 16
- 239000003755 preservative agent Substances 0.000 claims abstract description 16
- 230000002335 preservative effect Effects 0.000 claims abstract description 16
- 241000588653 Neisseria Species 0.000 claims abstract description 12
- 241000191940 Staphylococcus Species 0.000 claims abstract description 12
- 241000194017 Streptococcus Species 0.000 claims abstract description 12
- 241000204048 Mycoplasma hominis Species 0.000 claims abstract description 11
- 241000202921 Ureaplasma urealyticum Species 0.000 claims abstract description 11
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 8
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 8
- 241000588724 Escherichia coli Species 0.000 claims abstract description 6
- 108010052522 livetin Proteins 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000004088 foaming agent Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 20
- 210000001215 vagina Anatomy 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000006166 lysate Substances 0.000 claims description 15
- 238000001556 precipitation Methods 0.000 claims description 15
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 241000222122 Candida albicans Species 0.000 claims description 11
- 229940095731 candida albicans Drugs 0.000 claims description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 229960001631 carbomer Drugs 0.000 claims description 10
- 235000013601 eggs Nutrition 0.000 claims description 10
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical group CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 230000036039 immunity Effects 0.000 claims description 10
- 229940031551 inactivated vaccine Drugs 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 5
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 5
- 241000305071 Enterobacterales Species 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000010612 desalination reaction Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 235000013345 egg yolk Nutrition 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000011888 foil Substances 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000012982 microporous membrane Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229960002446 octanoic acid Drugs 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 206010046914 Vaginal infection Diseases 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 210000004994 reproductive system Anatomy 0.000 abstract description 3
- 201000008100 Vaginitis Diseases 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 230000031787 nutrient reservoir activity Effects 0.000 abstract 2
- 206010013700 Drug hypersensitivity Diseases 0.000 abstract 1
- 241000207201 Gardnerella vaginalis Species 0.000 abstract 1
- 241001523956 Parengyodontium album Species 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1253—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a yolk bioprotein foam filler which is mainly composed of 8-10% of multi-link yolk protein, 0.1-0.3% of preservative, 40-50% of matrix and the balance of a foamer.The multi-link yolk protein is yolk bioprotein capable of being combined with various pathogens, and the pathogens include, but not limited to ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, Escherichia coli, Gardnerella vaginalis, gonococcus and Tritirachium album.The yolk bioprotein foam filler is mainly composed of yolk bioprotein aiming at inhibiting pathogenic bacteria, can be combined with corresponding pathogens, can effectively inhibit and remove pathogens, is effective on most bacteria, mycete and mycoplasma, does not have impact on probiotics, can maintain health and physiological environment of a reproductive system, does not enter blood, is higher in safety during local use, is free of irritation and side effect on human body, dependency, drug resistance and hypersensitivity and can be used for various clinical therapeutic products for vaginitis.
Description
Technical field
The present invention relates to reproduction inflammation practical technique field, be specifically related to a kind of yolk bioprotein foam filling
Agent and preparation method thereof.
Background technology
Reproduction inflammation is modal female sex organ inflammation, for the disease that Out-patient Clinic of Department of Gynecology is common.Each age
Stage all can fall ill.Mainly by solving urine and humanoid mycoplasma, staphylococcus, streptococcus, Escherichia coli, vagina
Gartner bacterium, gonococcus, Candida albicans etc. is caused.Normal healthy women, due to anatomy and bioid
Feature, vagina has nature defense function to the intrusion of pathogen；When the natural defense function of vagina is destroyed,
Then pathogen is prone to invade, and causes colpitis.
At present suppression pathogen (bacterium, mould, the mycoplasma) composition of conventional composite washing lotion mainly with Chinese medicine,
Chemical drug, antibiotic are main.Conventional medicament can produce side effect in various degree in treatment simultaneously, it is difficult to selectivity
Killing pathogen, destroy the physiological environment of reproductive system, pathogen is easily generated drug resistance.
Accordingly, it would be desirable to develop a kind of non-stimulated to human body, without any side effects, do not produce dependence and resistance
Property, without anaphylaxis, novel medicine safely and efficiently.
Summary of the invention
Present invention solves the technical problem that and be to provide a kind of yolk bioprotein foam tamping and preparation side thereof
Method, yolk bioprotein foam tamping can targeting inactivating pathogens, non-stimulated to human body, secondary make without any
With, do not produce dependence and drug resistance, without anaphylaxis, safe and efficient.
The technical scheme is that
A kind of yolk bioprotein foam tamping, by mass percentage, main component is as follows: 8-20% is many
Connection livetin, 0.1-0.3% preservative, 40-50% matrix, surplus are foaming agent.
Further, described multi-joint livetin is the yolk bioprotein that can combine with multiple pathogens,
Described pathogen includes but not limited to Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, large intestine bar
Bacterium, vagina Gartner bacterium, gonococcus, Candida albicans.
Further, the preparation method of described multi-joint livetin is:
(1) Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, big is cultivated respectively with culture medium
Enterobacteria, vagina Gartner bacterium, gonococcus, Candida albicans, the thalline obtained is respectively with formalin-inactivated, breast
Change and make oil emulsion inactivated vaccine；
(2) product and normal healthy hens of laying eggs will have been opened respectively by above-mentioned steps (1) without artificial immunity
The inactivated vaccine obtained carries out immunity, takes egg isolated yolk liquid that hen produces；
(3) egg yolk liquid that step (2) obtains is mixed by the volume ratio of 1:1-5 with sterile purified water,
350-500rpm vibrates 15-30min, then the volume ratio pressing 1:2 adds sterile purified water, and 600rpm vibrates
5-10min, regulates pH to 5.1, and 4 DEG C stand 10 hours, and then 6000rpm is centrifuged 10 minutes, collect
Supernatant；
(4) the equal-volume saturated ammonium sulfate aqueous solution is added in the supernatant that step (3) obtains, 4 DEG C of standings
12 hours, 8000rpm was centrifuged 20 minutes, takes precipitation；Obtained by dissolving with distilled water by the mass ratio of 1:6
Precipitation, obtain lysate, be subsequently adding the caprylic acid relative to gained lysate 1.3 ‰, mixing；
(5) by the volume ratio of 1:2, the saturated ammonium sulfate aqueous solution and step (4) are obtained lysate to mix, 4 DEG C
Standing 12 hours, 8000rpm is centrifuged 20 minutes, takes precipitation, by the mass ratio of 1:4 with aseptic, pH7.2,
The PBS of 0.01M dissolves, and the solution 100Ku milipore filter bag obtained carries out desalination concentration, obtains dense
Contracting liquid；
(6) concentrate that step (5) obtains adds the formaldehyde of 0.05-0.1%, then at sealing state
Lower room temperature stands 3-5 hour, then with filtering with microporous membrane, obtains filtrate, is multi-joint livetin.
Further, described preservative is selected from ethyl-para-hydroxybenzoate, butyl p-hydroxybenzoate, sorbic acid
Any one or more in potassium, Sodium Benzoate, ethyl-para-hydroxybenzoate.
Further, described foaming agent is K12 foaming agent or AES foaming agent.
The preparation method of a kind of yolk bioprotein foam tamping, comprises the following steps:
(1) substrate preparation: take carbomer, glycerine, propane diols, purifying by the weight ratio of 3:4:6:100:1
Water, triethanolamine, insert in vacuum stirring pot by carbomer, adds glycerine, propane diols stirring, adds and purify
Water-swellable 30 hours, add triethanolamine stirring, be prepared as clear gel, obtain matrix, stand-by；
(2) in matrix, multi-joint livetin, preservative, foaming agent stirring homogeneous are added by described proportioning,
Load in disposable injector, additional PVC foil sealing, packaging.
Compared with prior art, the useful effect of the present invention is embodied in:
(1) present invention is mainly to have the yolk bioprotein of specific aim suppression pathogen, it is possible to phase
Answer pathogen to combine, thus effectively suppress, remove pathogen, block genital tract bacterium, mould, Zhi Yuan
Body-sensing contaminates, and prevention vagina infection occurs.
(2) the suppression pathogenic bacteria of the property of the present invention is directed to, and do not affect beneficial bacterium, safeguard the health of reproductive system
Physiological environment, alleviates vagina inflammatory reaction, reduces vaginal fluid amount, be effectively improved vagina cleanness degree, reduction
Vaginal pH, does not enter blood, locally safety in utilization higher.
(3) the yolk bioprotein of the present invention is the protein affine with human height, non-stimulated to human body,
Without any side effects, do not produce dependence and drug resistance, without anaphylaxis, safe and efficient.
(4) present invention can be used for various colpitic clinical treatment product, and targeting inactivating pathogens, to absolutely
Most bacterium, mould, mycoplasma is the most effective.
Detailed description of the invention
Embodiment 1:
A kind of yolk bioprotein foam tamping, by mass percentage, main component is as follows: 8% multi-joint ovum
Yellow albumen, 0.1% preservative, 40% matrix, surplus are foaming agent.
Wherein, described multi-joint livetin is the yolk bioprotein that can combine with multiple pathogens, described
Pathogen include but not limited to Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, Escherichia coli,
Vagina Gartner bacterium, gonococcus, Candida albicans.Described preservative is ethyl-para-hydroxybenzoate.Described
Infusion is K12 foaming agent.
The preparation method of described multi-joint livetin is:
(1) Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, big is cultivated respectively with culture medium
Enterobacteria, vagina Gartner bacterium, gonococcus, Candida albicans, the thalline obtained is respectively with formalin-inactivated, breast
Change and make oil emulsion inactivated vaccine；
(2) product and normal healthy hens of laying eggs will have been opened respectively by above-mentioned steps (1) without artificial immunity
The inactivated vaccine obtained carries out immunity, takes egg isolated yolk liquid that hen produces；
(3) egg yolk liquid that step (2) obtains is mixed by the volume ratio of 1:1 with sterile purified water, 350rpm
Vibration 15min, then the volume ratio press 1:2 adds sterile purified water, 600rpm vibrates 5min, regulation pH
To 5.1,4 DEG C stand 10 hours, and then 6000rpm is centrifuged 10 minutes, collect supernatant；
(4) the equal-volume saturated ammonium sulfate aqueous solution is added in the supernatant that step (3) obtains, 4 DEG C of standings
12 hours, 8000rpm was centrifuged 20 minutes, takes precipitation；Obtained by dissolving with distilled water by the mass ratio of 1:6
Precipitation, obtain lysate, be subsequently adding the caprylic acid relative to gained lysate 1.3 ‰, mixing；
(5) by the volume ratio of 1:2, the saturated ammonium sulfate aqueous solution and step (4) are obtained lysate to mix, 4 DEG C
Standing 12 hours, 8000rpm is centrifuged 20 minutes, takes precipitation, by the mass ratio of 1:4 with aseptic, pH7.2,
The PBS of 0.01M dissolves, and the solution 100Ku milipore filter bag obtained carries out desalination concentration, obtains dense
Contracting liquid；
(6) concentrate that step (5) obtains adds the formaldehyde of 0.05%, room the most in sealed states
Gentle and quiet put 3-5 hour, then with filtering with microporous membrane, obtain filtrate, be multi-joint livetin.
The preparation method of this yolk bioprotein foam tamping is:
(1) substrate preparation: take carbomer, glycerine, propane diols, purifying by the weight ratio of 3:4:6:100:1
Water, triethanolamine, insert in vacuum stirring pot by carbomer, adds glycerine, propane diols stirring, adds and purify
Water-swellable 30 hours, add triethanolamine stirring, be prepared as clear gel, obtain matrix, stand-by；
(2) in matrix, multi-joint livetin, preservative, foaming agent stirring homogeneous are added by described proportioning,
Load in disposable injector, additional PVC foil sealing, packaging.
Embodiment 2:
A kind of yolk bioprotein foam tamping, by mass percentage, main component is as follows: 14% is multi-joint
Livetin, 0.2% preservative, 45% matrix, surplus are foaming agent.
Wherein, described multi-joint livetin is the yolk bioprotein that can combine with multiple pathogens, described
Pathogen include but not limited to Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, Escherichia coli,
Vagina Gartner bacterium, gonococcus, Candida albicans.Described preservative is butyl p-hydroxybenzoate.Described
Infusion is AES foaming agent.
The preparation method of described multi-joint livetin is:
(1) Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, big is cultivated respectively with culture medium
Enterobacteria, vagina Gartner bacterium, gonococcus, Candida albicans, the thalline obtained is respectively with formalin-inactivated, breast
Change and make oil emulsion inactivated vaccine；
(2) product and normal healthy hens of laying eggs will have been opened respectively by above-mentioned steps (1) without artificial immunity
The inactivated vaccine obtained carries out immunity, takes egg isolated yolk liquid that hen produces；
(3) egg yolk liquid that step (2) obtains is mixed by the volume ratio of 1:1-5 with sterile purified water, 425rpm
Vibration 22.5min, then the volume ratio press 1:2 adds sterile purified water, 600rpm vibrates 7.5min, regulates
PH to 5.1,4 DEG C stand 10 hours, and then 6000rpm is centrifuged 10 minutes, collect supernatant；
(4) the equal-volume saturated ammonium sulfate aqueous solution is added in the supernatant that step (3) obtains, 4 DEG C of standings
12 hours, 8000rpm was centrifuged 20 minutes, takes precipitation；Obtained by dissolving with distilled water by the mass ratio of 1:6
Precipitation, obtain lysate, be subsequently adding the caprylic acid relative to gained lysate 1.3 ‰, mixing；
(5) by the volume ratio of 1:2, the saturated ammonium sulfate aqueous solution and step (4) are obtained lysate to mix, 4 DEG C
Standing 12 hours, 8000rpm is centrifuged 20 minutes, takes precipitation, by the mass ratio of 1:4 with aseptic, pH7.2,
The PBS of 0.01M dissolves, and the solution 100Ku milipore filter bag obtained carries out desalination concentration, obtains dense
Contracting liquid；
(6) concentrate that step (5) obtains adds the formaldehyde of 0.075%, room the most in sealed states
Gentle and quiet put 4 hours, then with filtering with microporous membrane, obtain filtrate, be multi-joint livetin.
The preparation method of this yolk bioprotein foam tamping is:
(1) substrate preparation: take carbomer, glycerine, propane diols, purifying by the weight ratio of 3:4:6:100:1
Water, triethanolamine, insert in vacuum stirring pot by carbomer, adds glycerine, propane diols stirring, adds and purify
Water-swellable 30 hours, add triethanolamine stirring, be prepared as clear gel, obtain matrix, stand-by；
(2) in matrix, multi-joint livetin, preservative, foaming agent stirring homogeneous are added by described proportioning,
Load in disposable injector, additional PVC foil sealing, packaging.
Embodiment 3:
A kind of yolk bioprotein foam tamping, by mass percentage, main component is as follows: 20% is multi-joint
Livetin, 0.3% preservative, 50% matrix, surplus are foaming agent.
Wherein, described multi-joint livetin is the yolk bioprotein that can combine with multiple pathogens, described
Pathogen include but not limited to Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, Escherichia coli,
Vagina Gartner bacterium, gonococcus, Candida albicans.Described preservative is potassium sorbate.Described foaming agent is
K12 foaming agent.
The preparation method of described multi-joint livetin is:
(1) Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, big is cultivated respectively with culture medium
Enterobacteria, vagina Gartner bacterium, gonococcus, Candida albicans, the thalline obtained is respectively with formalin-inactivated, breast
Change and make oil emulsion inactivated vaccine；
(2) product and normal healthy hens of laying eggs will have been opened respectively by above-mentioned steps (1) without artificial immunity
The inactivated vaccine obtained carries out immunity, takes egg isolated yolk liquid that hen produces；
(3) egg yolk liquid that step (2) obtains is mixed by the volume ratio of 1:5 with sterile purified water, 500rpm
Vibration 30min, then the volume ratio press 1:2 adds sterile purified water, 600rpm vibrates 10min, regulation pH
To 5.1,4 DEG C stand 10 hours, and then 6000rpm is centrifuged 10 minutes, collect supernatant；
(4) the equal-volume saturated ammonium sulfate aqueous solution is added in the supernatant that step (3) obtains, 4 DEG C of standings
12 hours, 8000rpm was centrifuged 20 minutes, takes precipitation；Obtained by dissolving with distilled water by the mass ratio of 1:6
Precipitation, obtain lysate, be subsequently adding the caprylic acid relative to gained lysate 1.3 ‰, mixing；
(5) by the volume ratio of 1:2, the saturated ammonium sulfate aqueous solution and step (4) are obtained lysate to mix, 4 DEG C
Standing 12 hours, 8000rpm is centrifuged 20 minutes, takes precipitation, by the mass ratio of 1:4 with aseptic, pH7.2,
The PBS of 0.01M dissolves, and the solution 100Ku milipore filter bag obtained carries out desalination concentration, obtains dense
Contracting liquid；
(6) concentrate that step (5) obtains adds the formaldehyde of 0.1%, room temperature the most in sealed states
Stand 5 hours, then with filtering with microporous membrane, obtain filtrate, be multi-joint livetin.
The preparation method of this yolk bioprotein foam tamping is:
(1) substrate preparation: take carbomer, glycerine, propane diols, purifying by the weight ratio of 3:4:6:100:1
Water, triethanolamine, insert in vacuum stirring pot by carbomer, adds glycerine, propane diols stirring, adds and purify
Water-swellable 30 hours, add triethanolamine stirring, be prepared as clear gel, obtain matrix, stand-by；
(2) in matrix, multi-joint livetin, preservative, foaming agent stirring homogeneous are added by described proportioning,
Load in disposable injector, additional PVC foil sealing, packaging.
Yolk bioprotein foam tamping of the present invention treatment reproduction inflammation test:
1, treatment target: choose bacterial vaginitis, colpomycosis and mycoplasma vaginitis patient altogether
200 examples, clinical manifestation is: vaginal fluid increases, vagina peculiar smell, pruritus vulvue, frequent micturition, odynuria and property
Handing over pain, leukorrhea has the symptoms such as blood.It is bisected into 2 groups at random, i.e. experimental group and control group, often organizes 100 people.
2, methods for the treatment of: experimental group uses the yolk bioprotein foam tamping of the embodiment of the present invention 2 preparation
Treating, methods for the treatment of, for monthly to use continuously 5-10 days in non-menstrual period, uses two months continuously；Comparison
Group uses the treatment of nitre Fu Taier nystatin expandable vaginal soft capsule, and by specification using method is treated, and uses two continuously
Month.
3, curative effect judging standard: the effective transference cure referring to be correlated with；Effectively refer to treated object sensation disease
Shape alleviates；Invalid refer to that result for the treatment of is felt inconspicuous by treated object.
4, statistics is shown in Table 1:
Table 1-treatment results is added up
| Group | Effective/people | Effectively/people | Invalid/people | Efficient/% |
| Experimental group | 87 | 13 | 0 | 100 |
| Control group | 52 | 32 | 16 | 84 |
5, conclusion: various bacteriums, mould, mycoplasma are caused by yolk bioprotein foam tamping of the present invention
Vagina infection the most effective, it is possible to block genital tract bacterium, mould, mycoplasma infection, improve vaginal microenvironment,
Alleviate vagina inflammatory reaction, reduce vaginal fluid amount, the vagina peculiar smell that causes for all kinds of colpitis, scabies
Itching, effect is notable.
The foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, for this area
Technical staff for, the present invention can have various modifications and variations.All within the spirit and principles in the present invention,
Any modification, equivalent substitution and improvement etc. made, should be included within the scope of the present invention.
Claims (6)
1. a yolk bioprotein foam tamping, it is characterised in that by mass percentage, mainly become
Divide as follows: the multi-joint livetin of 8-20%, 0.1-0.3% preservative, 40-50% matrix, surplus are foaming agent.
2. a kind of yolk bioprotein foam tamping as claimed in claim 1, it is characterised in that described
Multi-joint livetin is the yolk bioprotein that can combine with multiple pathogens, described pathogen include but not
Be limited to Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, Escherichia coli, vagina Gartner bacterium,
Gonococcus, Candida albicans.
3. a kind of yolk bioprotein foam tamping as claimed in claim 2, it is characterised in that described
The preparation method of multi-joint livetin is:
(1) Ureaplasma urealyticum, mycoplasma hominis, staphylococcus, streptococcus, big is cultivated respectively with culture medium
Enterobacteria, vagina Gartner bacterium, gonococcus, Candida albicans, the thalline obtained is respectively with formalin-inactivated, breast
Change and make oil emulsion inactivated vaccine；
(2) product and normal healthy hens of laying eggs will have been opened respectively by above-mentioned steps (1) without artificial immunity
The inactivated vaccine obtained carries out immunity, takes egg isolated yolk liquid that hen produces；
(3) egg yolk liquid that step (2) obtains is mixed by the volume ratio of 1:1-5 with sterile purified water,
350-500rpm vibrates 15-30min, then the volume ratio pressing 1:2 adds sterile purified water, and 600rpm vibrates
5-10min, regulates pH to 5.1, and 4 DEG C stand 10 hours, and then 6000rpm is centrifuged 10 minutes, collect
Supernatant；
(4) the equal-volume saturated ammonium sulfate aqueous solution is added in the supernatant that step (3) obtains, 4 DEG C of standings
12 hours, 8000rpm was centrifuged 20 minutes, takes precipitation；Obtained by dissolving with distilled water by the mass ratio of 1:6
Precipitation, obtain lysate, be subsequently adding the caprylic acid relative to gained lysate 1.3 ‰, mixing；
(5) by the volume ratio of 1:2, the saturated ammonium sulfate aqueous solution and step (4) are obtained lysate to mix, 4 DEG C
Standing 12 hours, 8000rpm is centrifuged 20 minutes, takes precipitation, by the mass ratio of 1:4 with aseptic, pH7.2,
The PBS of 0.01M dissolves, and the solution 100Ku milipore filter bag obtained carries out desalination concentration, obtains dense
Contracting liquid；
(6) concentrate that step (5) obtains adds the formaldehyde of 0.05-0.1%, then at sealing state
Lower room temperature stands 3-5 hour, then with filtering with microporous membrane, obtains filtrate, is multi-joint livetin.
The preparation method of a kind of yolk bioprotein foam tamping the most as claimed in claim 1, its feature
Being, described preservative is selected from ethyl-para-hydroxybenzoate, butyl p-hydroxybenzoate, potassium sorbate, benzene first
Any one or more in acid sodium, ethyl-para-hydroxybenzoate.
The preparation method of a kind of yolk bioprotein foam tamping the most as claimed in claim 1, its feature
Being, described foaming agent is K12 foaming agent or AES foaming agent.
The preparation method of a kind of yolk bioprotein foam tamping the most as claimed in claim 1, its feature
It is, comprises the following steps:
(1) substrate preparation: take carbomer, glycerine, propane diols, purifying by the weight ratio of 3:4:6:100:1
Water, triethanolamine, insert in vacuum stirring pot by carbomer, adds glycerine, propane diols stirring, adds and purify
Water-swellable 30 hours, add triethanolamine stirring, be prepared as clear gel, obtain matrix, stand-by；
(2) in matrix, multi-joint livetin, preservative, foaming agent stirring homogeneous are added by described proportioning,
Load in disposable injector, additional PVC foil sealing, packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610135567.9A CN105749277A (en) | 2016-03-10 | 2016-03-10 | Yolk bioprotein foam filler and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610135567.9A CN105749277A (en) | 2016-03-10 | 2016-03-10 | Yolk bioprotein foam filler and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105749277A true CN105749277A (en) | 2016-07-13 |
Family
ID=56333029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610135567.9A Pending CN105749277A (en) | 2016-03-10 | 2016-03-10 | Yolk bioprotein foam filler and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105749277A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105675865A (en) * | 2016-03-10 | 2016-06-15 | 陕西瑞凯生物科技有限公司 | Household intelligent detection reagent kit |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454901A (en) * | 2003-06-10 | 2003-11-12 | 雅臣药业集团（远东）有限公司 | Gynaecological anti-infective specificity IgY and its combined preparation |
| CN103342749A (en) * | 2013-07-29 | 2013-10-09 | 中国科学院微生物研究所 | Triple egg yolk antibody against newcastle disease virus, avian influenza virus and infectious bronchitis virus |
| CN103520107A (en) * | 2013-10-11 | 2014-01-22 | 徐克之 | Foaming agent for vaginal packing |
| CN104474547A (en) * | 2015-01-07 | 2015-04-01 | 蓝佳堂生物医药（福建）有限公司 | Vaginal infection prevention immune globulin compound preservative |
-
2016
- 2016-03-10 CN CN201610135567.9A patent/CN105749277A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454901A (en) * | 2003-06-10 | 2003-11-12 | 雅臣药业集团（远东）有限公司 | Gynaecological anti-infective specificity IgY and its combined preparation |
| CN103342749A (en) * | 2013-07-29 | 2013-10-09 | 中国科学院微生物研究所 | Triple egg yolk antibody against newcastle disease virus, avian influenza virus and infectious bronchitis virus |
| CN103520107A (en) * | 2013-10-11 | 2014-01-22 | 徐克之 | Foaming agent for vaginal packing |
| CN104474547A (en) * | 2015-01-07 | 2015-04-01 | 蓝佳堂生物医药（福建）有限公司 | Vaginal infection prevention immune globulin compound preservative |
Non-Patent Citations (2)
| Title |
|---|
| 李梦东主编: "《实用传染病学 第2版》", 30 April 1998, 人民卫生出版社 * |
| 罗明生等主编: "《药剂辅料大全 第2版》", 31 January 2006, 四川科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105675865A (en) * | 2016-03-10 | 2016-06-15 | 陕西瑞凯生物科技有限公司 | Household intelligent detection reagent kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5571520A (en) | Molecular crystal redox device for pharmaceuticals | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN102943006B (en) | Essential oil soap with bacterial killing and bacterial inhibiting functions | |
| CN103920072A (en) | Chitosan antibacterial gel and preparation method thereof | |
| CN103432287B (en) | Camellia oleosa seed lavipeditum powder and preparation method thereof | |
| CN104474547A (en) | Vaginal infection prevention immune globulin compound preservative | |
| CN109288889A (en) | A kind of antibacterial gynecological composition, gel and preparation method thereof | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN105456548A (en) | Foam disinfectant for medical use and preparation process of foam disinfectant | |
| CN105148059A (en) | Plant oil external liniment capable of repelling mosquitos and preparation method thereof | |
| CN101543658A (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN110585418A (en) | External use disinfection essential oil emulsion for women and production process thereof | |
| CN106109587A (en) | A kind of pharmaceutical composition repairing microecology in vaginas of women balance | |
| CN108404111A (en) | One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component | |
| CN105749277A (en) | Yolk bioprotein foam filler and preparation method thereof | |
| CN109055047A (en) | A kind of mosquito-proof children laundry detergent | |
| CN102755578B (en) | Washing liquid for treating gynecologic diseases and preparation method thereof | |
| CN103213226A (en) | Preparation method of antisepsis and anti-inflammation lubrication-type condom containing natural cinnamyl aldehyde | |
| CN105535170A (en) | Compound male private part nursing lotion and preparation method thereof | |
| CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN109260257A (en) | A kind of medical disinfectant and preparation method thereof | |
| CN111481567B (en) | Compound ozone oil and preparation method and application thereof | |
| CN103599437B (en) | One treats colpitic traditional Chinese medicine liquid | |
| CN106177274A (en) | A kind of conception control gel composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180905 Address after: 710065 room 2, No. 11, Tang Yan Nan Road, Xi'an high tech Zone, Shaanxi, China 21004 Applicant after: Xi'an Yu Zi Biotechnology Co., Ltd. Address before: 712000 Shaanxi Xi'an Xixian New District Feng Xi New Town fishing area development zone (Xianyang Xian Xiang health products factory) Applicant before: SHAANXI RUIKAI BIOTECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160713 |
|
| RJ01 | Rejection of invention patent application after publication |